Skip to main content
Antonin Levy on Muck Rack

Antonin Levy

As seen in: Nature, JAMA Oncology, Cell Press, The Lancet, Lexology, Future Medicine, European Journal of Cancer, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Antonin

Contact Antonin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Unresectable stage III non-small-cell lung cancer: state of the art and challenges - Nature Reviews Clinical Oncology

|
By Jordi Remon, Antonin Levy, Martina Bortolot, Natasha Leighl, Martin Reck
| Nature Verified
Abstract Despite advances in immunotherapy, unresectable stage III non-small-cell lung cancer (NSCLC) remains a highly challenging disease, with only around one-third of patients remaining disease-free at 5 years. The PACIFIC trial established consolidation with the anti-PD-L1 antibody durvalumab after concurrent chemoradiotherapy as the standard-of-care approach.
Open in Who Shared Issue with article?

Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results - Signal Transduction and Targeted Therapy

|
By Antonin Levy
| Nature Verified
Abstract Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable biomarkers to predict which patients will benefit are lacking.
Open in Who Shared Issue with article?

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients

|
By Jianzhou Chen, Antonin Levy, Guoxin Cai, Marine Fidelle, Conrad Rauber, Pierre Ly, Gianmarco Piccinno, Peng Liu, Sylvère Durand, Misha Mao, Liwei Zhao, Valerio Iebba, Hannah Felchle, Julius Clemens Fischer, Simon Thomas, Tim F. Greten, Jennifer Jones, Cecilia Monge, Sandra Demaria, Silvia C. Formenti, Lorenzo Belluomini, Christophe Massard, Pierre Blanchard, Michele Mondini, Lydia Meziani, Yizhou Zhan, Daphné Morel, Roger Sun, Monica Mangoni, Vanessa Di Cataldo, Maike Trommer, Simone Wegen, Rachel P. Riechelmann, Pierre-Edouard Fournier, Nicola Segata, Peter Holicek, Lorenzo Galluzzi, Aitziber Buqué, Lisa Derosa, Guido Kroemer, Laurence Zitvogel, Eric Deutsch, Ai-Ling Tian, Xuehan Huang, Eugénie Pizzato, Lisa Sitterle, Valeria Dionisi, Charlotte Robert, Clément Quevrin, Eloise Lopes, Céline Clémenson, Chengbing Zeng, Qingxin Cai, Pierre-Antoine Laurent, Chiara Arilli, Sebastian Neppl, Marcos P. Camandaroba, Elson Santos Neto, Chuangzhen Chen
| Cell Press Verified
Keywords: cancer radiotherapy gut microbiota Christensenella minuta bile acids dendritic cells tumor immunosurveillance metabolomics Introduction Preclinical models suggest that the combination of radiotherapy (RT), including stereotactic ablative radiotherapy (SABR) and immune checkpoint blockade (ICB), mediates synergistic anti-tumor immune responses not only at the local site but also on distal, non-irradiated tumors, known as “abscopal” effects.1,2,3 Hundreds of trials, including ours,...
Open in Who Shared Issue with article?
See all 25 articles